COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
Tweet
  StudiesStudies
  Global AdoptionAdoption
  Submit FeedbackFeedback
00.250.50.7511.251.51.752+Derwand0.21[0.03-1.47]death1/14113/377RRCITreatmentControlThomas (RCT)0.88[0.39-1.99]recov. time5850Tau​2 = 0.44; I​2 = 41.3%Early treatment0.58[0.16-2.11]1/19913/42742% improvementCarlucci0.62[0.45-0.86]death/HPC411521RRCITreatmentControlYao0.66[0.41-1.07]death73/19621/46Frontera0.63[0.44-0.91]death121/1,006424/2,467Abd-Elsalam (RCT)0.99[0.30-3.31]death5/965/95Tau​2 = 0.00; I​2 = 0.0%Late treatment0.64[0.55-0.74]199/1,709450/3,12936% improvementSeet (CLUS. RCT)0.50[0.34-0.75]severe case33/63464/619OT​1RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP0.50[0.34-0.75]33/63464/61950% improvementYasui0.07[0.01-0.54]ventilation1/206/9RRCITreatmentControlJothimani0.10[0.01-1.76]death0/205/27Berrocal0.55[0.23-1.31]death5/3126/89Tau​2 = 0.88; I​2 = 51.6%Sufficiency0.22[0.05-0.96]6/7137/12578% improvementAll studies0.61[0.52-0.71]239/2,613564/4,30039% improvement10 zinc COVID-19 studiesc19zinc.com 5/15/211 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 6.2%; Z = 6.45 (p < 0.0001)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Derwand0.21[0.03-1.47]1/14113/377RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment0.21[0.03-1.47]1/14113/37779% improvementYao0.66[0.41-1.07]73/19621/46RRCITreatmentControlFrontera0.63[0.44-0.91]121/1,006424/2,467Abd-Elsalam (RCT)0.99[0.30-3.31]5/965/95Tau​2 = 0.00; I​2 = 0.0%Late treatment0.64[0.54-0.76]199/1,298450/2,60836% improvementJothimani0.10[0.01-1.76]0/205/27RRCITreatmentControlBerrocal0.55[0.23-1.31]5/3126/89Tau​2 = 0.26; I​2 = 18.6%Sufficiency0.42[0.13-1.41]5/5131/11658% improvementAll studies0.63[0.54-0.74]205/1,490494/3,10137% improvement6 zinc COVID-19 mortality resultsc19zinc.com 5/15/21Tau​2 = 0.00; I​2 = 0.0%; Z = 5.60 (p < 0.0001)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Jothimani0.08[0.00-1.25]0/207/27RRCITreatmentControlBerrocal0.47[0.26-0.83]9/3155/89Tau​2 = 0.60; I​2 = 35.8%Sufficiency0.32[0.08-1.37]9/5162/11668% improvementAll studies0.32[0.08-1.37]9/5162/11668% improvement2 zinc COVID-19 ICU resultsc19zinc.com 5/15/21Tau​2 = 0.60; I​2 = 35.8%; Z = 1.53 (p = 0.063)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Derwand0.18[0.07-0.54]4/14158/377RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment0.18[0.07-0.54]4/14158/37782% improvementAbd-Elsalam (RCT)0.96[0.57-1.65]9695RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment0.96[0.57-1.65]0/960/954% improvementAll studies0.44[0.09-2.25]4/23758/47256% improvement2 zinc COVID-19 hospitalization resultsc19zinc.com 5/15/21Tau​2 = 1.21; I​2 = 87.9%; Z = 0.98 (p = 0.16)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Seet (CLUS. RCT)0.73[0.41-1.05]300/634433/619OT​1RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP0.73[0.41-1.05]300/634433/61927% improvementAll studies0.73[0.66-0.81]300/634433/61927% improvement1 zinc COVID-19 case resultc19zinc.com 5/15/211 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 6.32 (p < 0.0001)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Yasui0.07[0.01-0.54]ventilationRRCIJothimani0.10[0.01-1.76]deathBerrocal0.55[0.23-1.31]deathAll studies0.22[0.05-0.96]78% improvement3 zinc COVID-19 sufficiency studiesc19zinc.com 5/15/21Tau​2 = 0.88; I​2 = 51.6%; Z = 2.01 (p = 0.022)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Derwand0.21[0.03-1.47]death1/14113/377RRCITreatmentControlThomas (RCT)0.88[0.39-1.99]recov. time5850Tau​2 = 0.44; I​2 = 41.3%Early treatment0.58[0.16-2.11]1/19913/42742% improvementCarlucci0.62[0.45-0.86]death/HPC411521RRCITreatmentControlYao0.66[0.41-1.07]death73/19621/46Frontera0.63[0.44-0.91]death121/1,006424/2,467Abd-Elsalam (RCT)0.99[0.30-3.31]death5/965/95Tau​2 = 0.00; I​2 = 0.0%Late treatment0.64[0.55-0.74]199/1,709450/3,12936% improvementSeet (CLUS. RCT)0.50[0.34-0.75]severe case33/63464/619OT​1RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP0.50[0.34-0.75]33/63464/61950% improvementYasui0.07[0.01-0.54]ventilation1/206/9RRCITreatmentControlJothimani0.10[0.01-1.76]death0/205/27Berrocal0.55[0.23-1.31]death5/3126/89Tau​2 = 0.88; I​2 = 51.6%Sufficiency0.22[0.05-0.96]6/7137/12578% improvementAll studies0.61[0.52-0.71]239/2,613564/4,30039% improvement10 zinc COVID-19 serious outcomesc19zinc.com 5/15/211 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 6.2%; Z = 6.45 (p < 0.0001)Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Derwand0.21[0.03-1.47]death1/14113/377RRCITreatmentControlDerwand0.18[0.07-0.54]hosp.4/14158/377Thomas (RCT)0.88[0.39-1.99]recov. time5850Carlucci0.62[0.45-0.86]death/HPC411521Yao0.66[0.41-1.07]death73/19621/46Frontera0.63[0.44-0.91]death121/1,006424/2,467Frontera0.76[0.60-0.96]death121/1,006424/2,467Abd-Elsalam (RCT)0.99[0.30-3.31]death5/965/95Abd-Elsalam (RCT)0.66[0.19-2.26]ventilation4/966/95Abd-Elsalam (RCT)0.94[0.55-1.62]no recov.20/9621/95Abd-Elsalam (RCT)0.96[0.57-1.65]hosp. time9695Seet (CLUS. RCT)0.50[0.34-0.75]severe case33/63464/619OT​1Seet (CLUS. RCT)0.73[0.41-1.05]cases300/634433/619OT​1Yasui0.07[0.01-0.54]ventilation1/206/9Jothimani0.10[0.01-1.76]death0/205/27Jothimani0.08[0.00-1.25]ICU0/207/27Berrocal0.55[0.23-1.31]death5/3126/89Berrocal0.47[0.26-0.83]ICU9/3155/89zinc COVID-19 outcomesc19zinc.com 5/15/21Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary; multiple approaches are required to protect all people from all existing and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit